Dextroamphetamine
Viewing r1 — May 3, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Dextroamphetamine (d-amphetamine) — dex, dexies — is a synthetic stimulant of the phenethylamine class. It is the more potent half of amphetamine, with 3–5× stronger brain stimulation than levoamphetamine.[1] It works by flooding the synapse with dopamine and norepinephrine, producing its characteristic drive and focus.[2]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
methamphetamine, lisdexamfetamine, mixed amphetamine salts +1 moremethamphetamine, lisdexamfetamine, mixed amphetamine salts, methylphenidate show less
Amphetamine was first synthesized in 1887; Gordon Alles characterized its stimulant properties in 1927 while searching for an asthma drug.[3] The dextro form became one of medicine's most prescribed stimulants; a major review confirmed amphetamines as the most effective ADHD medication for children.[4] It remains FDA-approved for ADHD and narcolepsy, though lisdexamfetamine has largely replaced it in many markets.
Subjective effects include heightened focus, mental clarity, increased motivation, euphoria, and appetite suppression. The overall character is one of focused drive — sustained mental acceleration and heightened confidence, closer to an idealized concentration state than to intoxication. Characteristic unsought effects include insomnia, jaw tension, anxiety, and a depressive crash as the drug wears off.
Dextroamphetamine carries high psychological dependence liability and cardiovascular toxicity that worsens with chronic use;[5] the FDA warns of sudden cardiac death in people with structural heart problems.[1] Tolerance builds through receptor adaptation, but intermittent use can instead strengthen the reward response — driving compulsive escalation.[6][7] Nine decades of clinical use make dextroamphetamine one of the best-characterized stimulants in medicine.
History[edit]
Discovery
Racemic amphetamine was first synthesized in 1887, though its stimulant potential went unrecognized.[3] Gordon Alles independently resynthesized it in 1927 while searching for an asthma drug, tested it on himself, and filed a patent for amphetamine sulfate in 1932.[3] The more potent dextro form was identified shortly after, leading to Dexedrine as a more targeted clinical formulation.
Clinical and military significance
Amphetamines saw massive wartime deployment — the Royal Air Force approved Benzedrine in 1942, distributing an estimated 72 million tablets to British forces during the conflict.[8] A 2018 review later confirmed amphetamines as the most effective pharmacological ADHD treatment for children and adolescents.[4]
Regulation and modern use
Widespread non-medical use through the 1950s–70s drove increasing regulation, culminating in Schedule II classification under the US Controlled Substances Act in 1970. Dexedrine remains FDA-approved for ADHD and narcolepsy, though lisdexamfetamine (Vyvanse) — a prodrug that releases d-amphetamine in the body — has largely replaced it in many markets.
The name amphetamine derives from alpha-methylphenethylamine. Dextroamphetamine takes its prefix from the Latin dexter ("right"), referring to the molecule's optical rotation. Widely prescribed formulations include Dexedrine, Dextrostat, Attentin, and Procentra. Adderall — a mixed salt containing a 75:25 ratio of dextro- to levo-amphetamine — became one of the most recognized stimulant brand names in American culture.
Chemistry[edit]
Structural class
Dextroamphetamine belongs to the phenethylamine class. Its molecular formula is C₉H₁₃N (molecular weight 135.21 g/mol). The alpha-methyl group on the backbone resists rapid breakdown — this is why effects last hours rather than minutes. The same scaffold underlies methamphetamine, MDMA, and many other stimulants.
Pharmacology[edit]
Mechanism of action
Dextroamphetamine enters nerve cells through the transporters that normally move dopamine and norepinephrine, then runs them in reverse — flooding the synapse with both chemicals.[9][10] This reverse-transport mechanism is distinct from cocaine, which simply blocks reuptake.[11]
Inside the nerve cell, dextroamphetamine also disrupts the storage containers that hold dopamine, leaking their contents into the cell interior and providing more fuel for the outward flood at the surface.[12]
Pharmacokinetics
Oral bioavailability is approximately 90%, with peak blood levels reached around 3 hours after a dose.[1] Effects last 9–11 hours in adults, though urinary pH shifts this significantly — alkaline conditions prolong effects, acidic conditions shorten them.[1]
Neuroscience[edit]
Where it acts
The euphoric and reinforcement come from a dopamine surge in the brain's mesolimbic pathway — the connection from the midbrain to the nucleus accumbens.[13] The therapeutic benefit in ADHD comes from a different circuit: norepinephrine and dopamine in the prefrontal cortex improve attention and impulse control.[14]
Why it matters
Daily dosing produces tolerance — receptor adaptation and depleted neurotransmitter stores — so the same dose feels weaker over time.[7]
Intermittent use does the opposite: it progressively strengthens the rewarding effects, a change that can persist for months and may explain the chronic relapsing pattern of amphetamine addiction.[6]
The dose and duration at which dextroamphetamine causes measurable dopamine nerve damage in humans is unknown — most data extrapolate from methamphetamine or animal models.[15] Whether genetic variation in DAT expression could meaningfully guide individual dosing also remains unquantified.[16]
Subjective Effects[edit]
Dextroamphetamine's defining quality is focus without intoxication. The experience centers on heightened mental clarity and goal-directed energy — a state that feels like an idealized version of concentration. The drive is clean: no serotonergic warmth, no perceptual shift, no dreamlike quality.
Compared to cocaine, dextroamphetamine produces longer, less compulsive stimulation with more sustained cognitive lift. Relative to MDMA, the experience is purely stimulant — absent the empathogenic warmth characteristic of entactogens. At equivalent doses, it most closely resembles methamphetamine, though with lower peak euphoria.
Effect Grid
At common doses (10–16 mg oral), the full stimulant profile manifests. Thought acceleration becomes prominent, accompanied by increased motivation, talkativeness, and a sense of confidence. Euphoria is present in most individuals, though its intensity varies substantially with DAT gene polymorphisms — some users experience pronounced mood elevation while others note primarily cognitive enhancement without hedonic effects.
Cardiovascular activation becomes measurable: systolic blood pressure rises 5–15 mmHg, heart rate increases 10–20 bpm, and appetite suppression is significant. Jaw clenching, increased sweating, and urinary retention may occur. Pupil dilation is noticeable.
Total subjective duration is 4–6 hours for immediate-release, with residual wakefulness extending several hours beyond. Sleep is impractical for 8+ hours post-dose.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tinnitus · Auditory hallucinations · External hallucinations · Shadow people
Pupil dilation · Wakefulness · Dry mouth · Physical fatigue · Heart rate perception changes · Restlessness · Body high · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Breathing alteration · Headache · Sexual arousal enhancement · Trembling · Bodily lightness · Nausea · Pain suppression · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Motor control enhancement · Constipation · Dizziness · Involuntary body movements · Sexual arousal suppression · Vomiting · Tactile hallucination
Heart rate perception changes · Restlessness · Body high · Bruxism · Dehydration sensation · Excessive sweating · Muscle tension · Respiratory stimulation · Breathing alteration · Headache · Sexual arousal enhancement · Trembling · Bodily lightness · Nausea · Pain suppression · Spontaneous body sensations · Tactile euphoria · Tingling / electric sensations · Motor control enhancement · Constipation · Dizziness · Involuntary body movements · Sexual arousal suppression · Vomiting · Tactile hallucination
Motivation enhancement · Immersion enhancement · Thought acceleration · Analysis enhancement · Information processing enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Memory enhancement · Motivation suppression · Pattern recognition enhancement · Thought organization · Creativity enhancement · Language enhancement · Aesthetic enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought loops · Humor enhancement · Cognitive impairment · Creativity suppression · Confusion · Thought disorganization · Delirium · Delusions
Analysis enhancement · Information processing enhancement · Cognitive dysphoria · Cognitive flexibility · Conceptual thinking · Memory enhancement · Motivation suppression · Pattern recognition enhancement · Thought organization · Creativity enhancement · Language enhancement · Aesthetic enhancement · Introspection enhancement · Multiple thought streams · Openness enhancement · Thought loops · Humor enhancement · Cognitive impairment · Creativity suppression · Confusion · Thought disorganization · Delusions
Irritability · Anhedonia · Emotional enhancement · Emotional lability · Anxiety suppression · Emotional suppression · Empathy enhancement · Empathy suppression · Mania
Emotional lability · Anxiety suppression · Emotional suppression · Empathy enhancement · Empathy suppression
Self-control enhancement · Sociability enhancement · Compulsive behavior reduction · Disinhibition · Ego inflation · Social connection · Sociability suppression · Social disconnection · Trust enhancement · Depersonalization · Derealization
Ego inflation · Social connection · Sociability suppression · Social disconnection · Trust enhancement · Depersonalization · Derealization
Mindfulness enhancement
Timeline
First alerts emerge as subtle wakefulness and slight mood brightening. Effects are sub-threshold and easily attributed to placebo.
Stimulation builds progressively. Concentration sharpens, energy increases, and appetite begins to diminish. Heart rate elevation becomes perceptible.
Maximum cognitive enhancement, euphoria, and psychomotor activation. Cardiovascular effects plateau at their highest. Tmax reached approximately 3 hours post-ingestion.
Effects sustain at moderate intensity. Focus remains enhanced but euphoria diminishes. Appetite suppression continues.
Gradual return toward baseline. Residual stimulation persists due to the 9-11 hour half-life. Fatigue may emerge as catecholamine stores deplete.
Residual wakefulness and mild appetite suppression. Some individuals report irritability or low mood during this phase.
⚠ Do not drive or operate machinery during the comedown period, as fatigue and impaired concentration may develop abruptly as residual stimulation fades.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 14 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- methamphetamine · lisdexamfetamine · mixed amphetamine salts
Toxicity
Acute toxicity
No formal human lethal dose is established, though death has occurred at doses of 20–25 mg/kg in sensitive individuals.[1] The therapeutic range of 5–60 mg/day provides a substantial safety margin in healthy people, though this narrows considerably in those with heart conditions.
Overdose produces agitation, dangerously elevated body temperature, rapid heart rate, high blood pressure, tremors, seizures, and stroke.[1] There is no antidote; treatment manages each symptom — benzodiazepines for seizures, active cooling for overheating, blood pressure medication, and continuous heart monitoring.[1]
Heart and circulation
Chronic use significantly raises blood pressure.[5] Cardiomyopathy, heart attack, and stroke are rare but documented adverse events.[1] The FDA has issued a black box warning for sudden cardiac death in patients with structural heart abnormalities — at both prescribed and misused doses.[1]
High-dose nerve damage
At high sustained doses, dextroamphetamine damages dopamine nerve terminals in the brain through oxidative stress and inflammation.[15][17] This effect requires sustained exposure far beyond normal clinical parameters.[15]
Pregnancy and breastfeeding
Use during pregnancy is associated with premature delivery, low birth weight, and preeclampsia.[1] Amphetamines concentrate in breast milk at 3–7× the level in the mother's blood; breastfeeding is contraindicated during use.[1]
Pediatric growth
Long-term stimulant use in children is associated with reduced weight and height gain; some evidence suggests growth normalizes after stopping.[18]
Psychological risks
Chronic high-dose use can produce paranoia, auditory hallucinations, and delusional thinking indistinguishable from paranoid schizophrenia.[7] The condition is reversible upon stopping in most cases, though resolution may take weeks.
Additional risks include worsening anxiety, depressive crashes after use, and mania induction in people with bipolar vulnerability.[1] Paranoia can occur even at therapeutic doses in sensitive individuals.[1]
Tolerance and dependence
Tolerance builds with repeated use — receptor adaptation and depleted neurotransmitter stores make the same dose feel progressively weaker.[7][6] Paradoxically, intermittent use can strengthen the reward response instead, potentially driving compulsive escalation.[6]
Stopping after chronic use brings fatigue, excessive sleep, low mood, anhedonia, appetite enhancement, and irritability lasting days to weeks.[18] Physical withdrawal is generally less severe than with alcohol or benzodiazepines. Dextroamphetamine is classified Schedule II in the US due to its high abuse potential.[1]
Drug interactions
Serotonergic combinations
Although dextroamphetamine has low serotonin activity alone, combining it with serotonin-raising drugs — SSRIs, SNRIs, triptans, or St. John's Wort — can push serotonin to dangerous levels, producing overheating, muscle rigidity, and seizures.[1] The risk is higher when certain antidepressants (fluoxetine, paroxetine) simultaneously slow amphetamine's breakdown.[1]
MAO inhibitors
Combining dextroamphetamine with monoamine oxidase inhibitors is contraindicated — the combination causes a massive norepinephrine surge, producing a life-threatening blood pressure crisis.[1] A minimum 14-day washout period is required after stopping any MAOI before starting dextroamphetamine. This applies to phenelzine, tranylcypromine, selegiline, linezolid, and methylene blue.[1]
Metabolic interactions
Certain antidepressants (fluoxetine, paroxetine, bupropion) slow amphetamine metabolism, raising blood levels and increasing adverse event risk. Antacids and thiazide diuretics make urine more alkaline, prolonging effects; vitamin C acidifies urine and shortens them.[1][19]
Stimulant stacking
Combining with other stimulants — cocaine, high-dose caffeine — adds cardiovascular stress, raising blood pressure and heart rate and increasing the risk of irregular heartbeat and stroke.[18]
Alcohol
Stimulants mask the feeling of intoxication, leading to overconsumption and delayed recognition of a dangerous blood alcohol level. Cardiovascular strain is additive.[18]
Contraindications
Absolute contraindications:
- Hypersensitivity to amphetamine or any formulation component
- Concurrent or recent (within 14 days) MAOI use
- Advanced hardening of the arteries
- Symptomatic heart disease
- Moderate-to-severe high blood pressure
- Overactive thyroid
- Narrow-angle glaucoma
- Agitated states
Relative contraindications:
- History of substance use disorder
- Bipolar disorder (risk of triggering mania)
- Psychotic disorders or family history of psychosis
- Pregnancy and breastfeeding
- Structural heart abnormalities (FDA black box warning — sudden cardiac death risk)
- Tourette syndrome or tic disorders
All contraindications derived from FDA prescribing information.[1]
Harm Reduction[edit]
Forms & Identification
Dextroamphetamine circulates primarily as pharmaceutical tablets and capsules, where identity is confirmed by imprint codes. In non-medical contexts, tablets may be crushed for snorting or dissolved for injection — both routes carry substantially higher cardiovascular risk and reinforcement potential than oral use.
Reagent testing is most relevant when tablets lack identifiable imprints or when powder is obtained outside pharmaceutical supply chains, where substitution with methamphetamine or other stimulants is possible.
Guidelines
- Test any non-pharmaceutical material with appropriate reagent kits before use
- Start with the lowest effective dose and wait for full onset before considering redosing
- Set a firm time limit — stimulant-driven productivity loops easily extend into sleep deprivation
- Eat a meal before dosing; appetite suppression makes it easy to go 8+ hours without food
- Keep water accessible and drink regularly — stimulants mask dehydration signals
- Avoid redosing in the afternoon or evening to protect sleep
- Have a sleep plan: a dark, cool room, no screens, and if needed, a non-stimulant sleep support
Set & Setting
The stimulant effect profile makes environmental context important. A calm, organized setting supports focused cognitive enhancement, while chaotic or high-stimulation environments can amplify anxiety, paranoia, and cardiovascular stress.
Adequate hydration, food availability, and a defined end-time help prevent the common pattern of redosing through fatigue. Those with anxiety disorders or cardiovascular conditions should approach with particular caution.
Aftercare & integration. The stimulant comedown — fatigue, low mood, irritability, appetite enhancement — reflects temporary neurotransmitter depletion and resolves within 1–3 days. Prioritize sleep, even if it requires a full day of rest. Eat nutrient-dense meals to replenish depleted stores.
Avoid redosing through the comedown; this extends the depletion cycle and accelerates tolerance. If use was for productivity, reflect honestly on whether the output justified the recovery cost — stimulant-assisted work often feels more productive than it is.
Recovery & Support
Amphetamine dependence is primarily psychological — the compulsion often centers on productivity, weight management, or euphoria rather than avoiding physical withdrawal. Professional support is especially important for those who began using to manage ADHD, as untreated ADHD persists after stopping and requires alternative management.
SMART Recovery and similar programs offer structured support for stimulant dependence. Medical consultation can help manage withdrawal and assess whether underlying ADHD requires treatment. Tapering under medical supervision reduces withdrawal severity.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, seizure, loss of consciousness, body temperature hot enough to feel through clothing, severe confusion, or stroke symptoms (sudden weakness on one side, slurred speech, facial drooping) require immediate medical attention. These are not normal stimulant side effects.
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Remove excess clothing and apply cool water if body temperature is dangerously elevated
- 4. Do not restrain the person unless they are in immediate danger of self-harm
- 5. Do not induce vomiting
- 6. If the person is unconscious, place them in the recovery position
What to tell the dispatcher: Name the substance (dextroamphetamine or amphetamine), estimated amount, time taken, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Dextroamphetamine is legally available by prescription in most jurisdictions and criminalized for non-medical possession and supply.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act, 1970) | FDA-approved for ADHD and narcolepsy; no refills permitted; 90-day maximum prescription[1] |
| United Kingdom | Class B, Schedule 2 (Misuse of Drugs Act 1971) | Class A if prepared for injection; possession up to 5 years imprisonment; supply up to 14 years[20] |
| Australia | Schedule 8 (Controlled Drugs) | Prescription-only under Poisons Standard; state-level permit requirements for prescribing[18] |
| Canada | Schedule III (CDSA) | Prescription required; possession offence up to 3 years imprisonment[21] |
| European Union | Varies by member state | Generally classified as prescription-only controlled substance; specific scheduling differs nationally |
The UK classification introduces a notable severity escalation: amphetamines prepared for injection are reclassified from Class B to Class A, carrying maximum penalties equivalent to heroin or cocaine possession.[20]
Legal status changes frequently and varies by jurisdiction. This information is not legal advice and may not reflect current law.
references
- [1]
- [2]
- [3]
- [4] ^abCortese S, Adamo N, Del Giovane C, et al. (2018) Comparative efficacy and tolerability of medications for ADHD in children, adolescents, and adults: a systematic review and network meta-analysis — The Lancet Psychiatry doi:10.1016/s2215-0366(18)30269-4
- [5] ^abChan M, Chan JJ, Wright JM (2025) Effect of amphetamines on blood pressure — Cochrane Database of Systematic Reviews doi:10.1002/14651858.cd007896.pub4
- [6] ^abcdGarcia V, Collins SA, Hernandez E, et al. (2025) A proposed mechanism for amphetamine-induced behavioral sensitization involving the vesicular monoamine transporter — Brain Research doi:10.1016/j.brainres.2025.149848